---
title: "Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 | PLX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285359838.md"
description: "Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 | PLX Stock News"
datetime: "2026-05-06T02:50:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285359838.md)
  - [en](https://longbridge.com/en/news/285359838.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285359838.md)
---

# Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 | PLX Stock News

Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 | PLX Stock News

### Related Stocks

- [PLX.US](https://longbridge.com/en/quote/PLX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)